menu
    • menu

    Find Dupilumab manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 36
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    2

    API Suppliers

    0

    USDMF

    0

    CEP/COS

    1

    JDMF

    0

    EU WC

    0

    KDMF

    0

    NDC API

    0

    VMF

    1

    Listed Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    60

    FDF Dossiers

    1

    FDA Orange Book

    17

    Europe

    4

    Canada

    36

    Australia

    2

    South Africa

    0

    Listed Dossiers

    36PROSPECTS

    217DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    14

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    1,714,709,394

    Annual Reports

    52,098

    Regulatory FDF Prices

    NA

    MARKET PLACE

    3

    API

    0

    FDF

    DIGITAL CONTENT

    5

    Data Compilation #PharmaFlow

    7

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    343

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set

    API SUPPLIERS

    read-more
    read-more

    01

    Shanghai Minbiotech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Regeneron Pharmaceuticals

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    PEGS Boston Summit
    Not Confirmed
    arrow

    Regeneron Pharmaceuticals

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PEGS Boston Summit
    Not Confirmed
    USDMF CEP/COS JDMF arrow-down
    ✖

    Registration Number : 305MF40023

    Registrant's Address : 777 Old Saw Mill River Road Tarrytown, NY 10591 USA

    Initial Date of Registration : 2023-07-05

    Latest Date of Registration :

    EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    JDMF

    read-more
    read-moreread-more

    01

    Regeneron Pharmaceuticals Inc.

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    Regeneron Pharmaceuticals Inc.

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Cell/Dupilumab Development Cell Bank

    Registration Number : 305MF40023

    Registrant's Address : 777 Old Saw Mill River Road Tarrytown, NY 10591 USA

    Initial Date of Registration : 2023-07-05

    Latest Date of Registration : 2023-07-05

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Shanghai Minbiotech

    China
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Dupilumab

    About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...

    Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in Nantong, Jiangsu and Jinan, Shandong, with more than 13,000㎡ of production sites. While supplying products to customers, the company also provides services such as technology development, technology transfer and technology exchange, aiming to provide customers with comprehensive supply and solutions in the biomedical industry. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Dupilumab SC Safety and Effect On Airway Inflammation In COPD Adults 40–85

    Details:

    Dupilumab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable July 08, 2025

    Sanofi Company Banner

    01

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dupilumab SC Safety and Effect On Airway Inflammation In COPD Adults 40–85

    Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    July 08, 2025

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Dupixent sBLA accepted for FDA priority review forbullous pemphigoid

    Details:

    Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Immunology Brand Name: Dupixent

    Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 18, 2025

    Sanofi Company Banner

    02

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Immunology

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dupixent sBLA accepted for FDA priority review forbullous pemphigoid

    Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways.

    Product Name : Dupixent

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    February 18, 2025

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    FDA Accepts Dupixent sBLA for Chronic Spontaneous Urticaria Treatment

    Details:

    Dupixent (dupilumab) is an approved monoclonal antibody works by inhibiting IL-4 and IL-13. It is being investigated for the treatment in 12 years and older with chronic spontaneous urticaria.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Immunology Brand Name: Dupixent

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 15, 2024

    Sanofi Company Banner

    03

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Immunology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    FDA Accepts Dupixent sBLA for Chronic Spontaneous Urticaria Treatment

    Details : Dupixent (dupilumab) is an approved monoclonal antibody works by inhibiting IL-4 and IL-13. It is being investigated for the treatment in 12 years and older with chronic spontaneous urticaria.

    Product Name : Dupixent

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 15, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participan...

    Details:

    Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neurodermatitis.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 14, 2024

    Sanofi Company Banner

    04

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injectio...

    Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neurodermatitis.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 14, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participan...

    Details:

    Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neurodermatitis.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 14, 2024

    Sanofi Company Banner

    05

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injectio...

    Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neurodermatitis.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    November 14, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Dupixent Achieves Significant Improvements in Bullous Pemphigoid Study

    Details:

    Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Immunology Brand Name: Dupixent

    Study Phase: Phase II/ Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 11, 2024

    Sanofi Company Banner

    06

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Immunology

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Dupixent Achieves Significant Improvements in Bullous Pemphigoid Study

    Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL4) and interleukin-13 (IL13) pathways.

    Product Name : Dupixent

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    September 11, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps

    Details:

    Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinosinusitis with Nasal Polyps.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IVProduct Type: Antibody, Unconjugated

    Sponsor: Andrew Thamboo

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable August 16, 2024

    Sanofi Company Banner

    07

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase IV

    Partner/Sponsor/Collaborator : Andrew Thamboo

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With ...

    Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Rhinosinusitis with Nasal Polyps.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    August 16, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

    Details:

    Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prurigo.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Dermatology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 05, 2024

    Sanofi Company Banner

    08

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Month...

    Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prurigo.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    March 05, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Japan Approves Dupixent® for Chronic Spontaneous Urticaria (CSU)

    Details:

    Dupixent (dupilumab) inhibits IL-4/IL-13 pathways and is approved for chronic spontaneous urticaria without immunosuppressive effects.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Immunology Brand Name: Dupixent

    Study Phase: Approved FDFProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 16, 2024

    Sanofi Company Banner

    09

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Immunology

    Highest Development Status : Approved FDF

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Japan Approves Dupixent® for Chronic Spontaneous Urticaria (CSU)

    Details : Dupixent (dupilumab) inhibits IL-4/IL-13 pathways and is approved for chronic spontaneous urticaria without immunosuppressive effects.

    Product Name : Dupixent

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    February 16, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

    Details:

    Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.


    Lead Product(s): Dupilumab,Inapplicable

    Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Antibody, Unconjugated

    Sponsor: Regeneron Pharmaceuticals

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 05, 2024

    Sanofi Company Banner

    10

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Lead Product(s) : Dupilumab,Inapplicable

    Therapeutic Area : Pulmonary/Respiratory Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Regeneron Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 ...

    Details : Dupilumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.

    Product Name : Undisclosed

    Product Type : Antibody, Unconjugated

    Upfront Cash : Inapplicable

    January 05, 2024

    Sanofi Company Banner

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injectable Solution In Pre-Filled Pen

    Dosage Strength : 300MG

    Packaging :

    Approval Date : 10-12-2019

    Application Number : 1171229018

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injectable Solution In Pre-Filled Syringe

    Dosage Strength : 300MG

    Packaging :

    Approval Date : 20-10-2017

    Application Number : 1171229006

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injectable Solution In Pre-Filled Pen

    Dosage Strength : 200MG

    Packaging :

    Approval Date : 10-12-2019

    Application Number : 1171229014

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injectable Solution In Pre-Filled Syringe

    Dosage Strength : 200MG

    Packaging :

    Approval Date : 10-12-2019

    Application Number : 1171229010

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injection Solution

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 30-09-2022

    Application Number : 28106739621

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 28-09-2017

    Application Number : 28106090618

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 09-05-2019

    Application Number : 28106349419

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 30-09-2022

    Application Number : 28106855221

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injection Solution

    Dosage Strength : 300mg

    Packaging :

    Approval Date : 30-09-2022

    Application Number : 28106739721

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Sanofi

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 300mg

    Packaging :

    Approval Date : 28-09-2017

    Application Number : 28105870016

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    REGENERON PHARMACEUTICALS

    U.S.A
    PEGS Boston Summit
    Not Confirmed
    arrow

    REGENERON PHARMACEUTICALS

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD :

    TE Code :

    DUPILUMAB

    Brand Name : DUPIXENT

    Dosage Form : INJECTABLE; INJECTION

    Dosage Strength : 150MG/ML

    Approval Date :

    Application Number : 761055

    RX/OTC/DISCN :

    RLD :

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Europe

    read-more
    read-more

    01

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injectable Solution In Pre-Filled Pen

    Dosage Strength : 300MG

    Packaging :

    Approval Date : 10-12-2019

    Application Number : 1171229018

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injectable Solution In Pre-Filled Pen

    Dosage Strength : 200MG

    Packaging :

    Approval Date : 10-12-2019

    Application Number : 1171229014

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Authorized

    Registration Country : Spain

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injectable Solution In Pre-Filled Syringe

    Dosage Strength : 200MG

    Packaging :

    Approval Date : 10-12-2019

    Application Number : 1171229010

    Regulatory Info : Authorized

    Registration Country : Spain

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Injection Solution

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 30-09-2022

    Application Number : 28106739621

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 09-05-2019

    Application Number : 28106349419

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 30-09-2022

    Application Number : 28106855221

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 300mg

    Packaging :

    Approval Date : 26-06-2020

    Application Number : 28106468220

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Prescription

    Registration Country : Denmark

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 300mg

    Packaging :

    Approval Date : 30-09-2022

    Application Number : 28106855321

    Regulatory Info : Prescription

    Registration Country : Denmark

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Approved

    Registration Country : Sweden

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 200mg

    Packaging :

    Approval Date : 06-05-2019

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Sanofi Winthrop Industrie

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Approved

    Registration Country : Sweden

    Dupilumab

    Brand Name : Dupixent

    Dosage Form : Solution For Injection

    Dosage Strength : 300mg

    Packaging :

    Approval Date : 17-10-2019

    Application Number : 2.02E+13

    Regulatory Info : Approved

    Registration Country : Sweden

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Australia

    read-more
    read-more

    01

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    sanofi-aventis Australia Pty Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Australia

    Dupilumab

    Brand Name : Dupixent

    Dosage Form :

    Dosage Strength :

    Packaging : 2

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Australia

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    South Africa

    read-more
    read-more

    01

    Sanofi Aventis South Africa (Pty) Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Originator

    Registration Country : South Africa

    Dupilumab

    Brand Name : Dupixent 200mg

    Dosage Form : INJ

    Dosage Strength : 200mg

    Packaging : 1.14X2mg

    Approval Date :

    Application Number :

    Regulatory Info : Originator

    Registration Country : South Africa

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Sanofi Aventis South Africa (Pty) Ltd

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : Generic

    Registration Country : South Africa

    Dupilumab

    Brand Name : Dupixent 300mg

    Dosage Form : INJ

    Dosage Strength : 300mg

    Packaging : 1X2mg

    Approval Date :

    Application Number :

    Regulatory Info : Generic

    Registration Country : South Africa

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    Top Pharma Companies & Drugs in 2024: Merck’s Keytruda maintains top spot as Novo’s semaglutide nips at its heels

    In 2024, Big Pharma players consolidated and maintained their dominance, even as innovation continued to reshape the pharmaceutical landscape. The primary change last year was the meteoric rise of glucagon-like peptide-1 (GLP-1) receptor agonists that treat diabetes and help in weight loss.Amongst drugmakers, Pfizer retained its numero uno spot with an impressive US$ 63.6 billion in prescription drug sales (up 7 percent from US$ 59.56 billion reported in 2023), despite ever-shrinking Comirnaty sales, which settled at US$ 5.35 billion in 2024 (from US$ 11.22 billion in 2023).Merck secured the second position with revenues of US$ 57.4 billion, a growth of 7 percent over 2023. This performance was predominantly fueled by Keytruda, which now accounts for more than half of Merck’s total pharmaceutical revenue. Johnson & Johnson came a close third with US$ 57 billion in prescription drug sales (up from US$ 54.76 billion in 2023).AbbVie held the fourth position with US$ 56.33 billion in sales, achieving 3.7 percent growth despite the ongoing erosion of Humira revenue. This flagship immunology drug saw sales plummet 37.6 percent to approximately US$ 9 billion, a US$ 5.4 billion reduction compared to 2023. Humira’s loss was offset by AbbVie’s newer immunology assets, particularly Skyrizi and Rinvoq, both of which demonstrated exceptional growth trajectories. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)European giants Astra, Roche, Novartis, Sanofi round out top 10 list; Novo, Lilly see astounding growthWhile the top four positions were dominated by American drugmakers, European giants dominated the lower half of the top 10 list.AstraZeneca secured the fifth spot with US$ 54.1 billion in sales, thereby posting impressive growth of 18.1 percent over 2023. Roche claimed the sixth position with US$ 50.9 billion in sales while Novartis ranked seventh — with sales of US$ 50.3 billion. Novartis' impressive 10.8 percent sales growth is attributed to its innovative medicines portfolio. Oncology therapies remained a cornerstone for both these Swiss drugmakers.Bristol Myers Squibb (BMS) secured eighth position with revenues of US$ 48.3 billion, representing 7.3 percent growth over the previous year. At US$ 45 billion, Eli Lilly posted 32 percent revenue growth last year. Its GLP-1 drug Mounjaro helped Lilly move up from the tenth in 2023 to the ninth spot last year.Sanofi landed the tenth position with US$ 42.6 billion in sales, propelled largely by the expanding indications of Dupixent. The French multinational has increasingly focused on this immunology blockbuster, while also garnering more sales from its vaccine and rare disease portfolios.Novo Nordisk merits a mention as it posted an incredible 26 percent year-on-year growth. It retained its eleventh spot with US$ 40.25 billion in sales. Novo’s growth was driven almost exclusively by the extraordinary success of its GLP-1 receptor agonist portfolio. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available)       Merck’s Keytruda retains throne with US$ 29.5 bn in sales, as Novo’s semaglutide nips at its heelsMoving on to drugs, Merck’s Keytruda (pembrolizumab) solidified its position as the world’s top-selling pharmaceutical product with sales exceeding US$ 29.5 billion and year-on-year growth of 17.88 percent (US$ 4.5 billion). This remarkable performance was driven by steady sales growth across more than 40 indications in the US. In 2024 alone, Keytruda secured four new approvals from the US Food and Drug Administration (FDA).However, Novo Nordisk’s semaglutide sales (Ozempic, Wegovy and Rybelsus) gave Keytruda a run for its money. Across the three blockbuster drugs, semaglutide earned the Danish drugmaker around US$ 28 billion — i.e. a year-on-year increase of 38 percent.Novo’s Ozempic (semaglutide) reached over US$ 16.7 billion in sales — a 20 percent increase from 2023. Originally approved in 2017 to improve glycemic control, Ozempic bagged additional approvals in 2020, and in January 2025. It is now approved to reduce the risk of major cardiovascular events, as well as to reduce cardiovascular risk and to lower the likelihood of chronic kidney disease in type 2 diabetes patients.Sales of Wegovy (semaglutide), the other blockbuster GLP-1 drug from Novo, grew by a whopping 85.7 percent to over US$ 8 billion.Sanofi and Regeneron’s Dupixent (dupilumab) secured the number three spot with sales of US$ 13.6 billion, representing an impressive 17.2 percent year-on-year growth. In 2024, Dupixent received three new approvals and one label update. Notably, it became the first-ever biologic medicine approved for patients with chronic obstructive pulmonary disease (COPD). View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) AbbVie’s post-Humira strategy pays off as Skyrizi surges 51%; Lilly’s Mounjaro posts 124% growthGilead Sciences’ HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) showed robust growth of 13.27 percent, touching sales of US$ 13.42 billion in 2024 and emerging as the fourth largest selling drug. Biktarvy now commands over 50 percent of the US HIV treatment market. Unlike many other drugs on this list, Biktarvy faces no immediate patent challenges, with key protections expected to remain intact until 2033.BMS and Pfizer’s anticoagulant Eliquis (apixaban) claimed the fifth position with US$ 13.33 billion in sales, representing a 9.21 percent year-on-year increase. AbbVie’s Skyrizi (risankizumab) emerged as one of the fastest-growing assets with a 50.95 percent year-on-year increase, generating US$ 11.71 billion in 2024 sales, thereby surpassing Humira’s (adalimumab) diminished sales.This impressive performance, combined with Rinvoq’s (upadacitinib) growth, has prompted  AbbVie to raise its long-term outlook for these products. The company now expects combined Skyrizi and Rinvoq revenues to exceed US$ 31 billion by 2027, with Skyrizi alone projected to generate over US$ 20 billion.Johnson & Johnson’s Darzalex (daratumumab) claimed the seventh position with US$ 11.67 billion in sales, representing 19.77 percent growth over 2023.Lilly’s Mounjaro (tirzepatide) demonstrated dramatic growth with sales increasing 123.51 percent to US$ 11.54 billion. This performance was complemented by Zepbound (tirzepatide, for weight loss), which contributed US$ 4.9 billion to Lilly’s revenue. By the end of 2024, Mounjaro received FDA approval for a new indication in obstructive sleep apnea (OSA), becoming the first and only prescription medicine for moderate-to-severe OSA in adults with obesity.Stelara (ustekinumab) ranked ninth, bringing J&J sales of US$ 10.36 billion, showing a modest decline of 4.91 percent from its 2023 sales.Vertex’s triple-combination therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) for treating cystic fibrosis rounded out the top ten list with sales of US$ 10.2 billion, up 14 percent from the previous year. View Our Interactive Dashboard on Top Drugs in 2024 by Sales (Free Excel Available) Our viewIn 2024, transformative therapies like GLP-1 receptor agonists drove growth in the pharmaceutical industry. This year, we expect GLP-1 drugs to dethrone Keytruda from the number one spot. Along with novel immunology agents, we expect GLP-1 drugs to realign the pharmaceutical market.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 15513

    https://www.pharmacompass.com/radio-compass-blog/top-pharma-companies-drugs-in-2024-merck-s-keytruda-maintains-top-spot-as-novo-s-semaglutide-nips-at-its-heels

    #PharmaFlow by PHARMACOMPASS
    24 Apr 2025
    Share Share

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi has 'vigorous defense planned' for Dupixent patent cliff
    Sanofi has 'vigorous defense planned' for Dupixent patent cliff

    24 Apr 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/sanofi-expects-extend-its-loe-dupixent-beyond-2031

    FIERCE PHARMA
    24 Apr 2026
    Share Share
    Sanofi Has 'Vigorous Defense Planned' For Dupixent Patent Cliff
    Sanofi Has 'Vigorous Defense Planned' For Dupixent Patent Cliff

    23 Apr 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/sanofi-expects-extend-its-loe-dupixent-beyond-2031

    FIERCE PHARMA
    23 Apr 2026
    Share Share
    Sanofi Defends Dupixent Patents Amid CEO Change
    Sanofi Defends Dupixent Patents Amid CEO Change

    23 Apr 2026

    // BIOSPACE

    https://www.biospace.com/business/sanofi-defends-dupixent-patents-but-execs-insist-it-has-nothing-to-do-with-ceo-change

    BIOSPACE
    23 Apr 2026
    Share Share
    Dupixent Approval For Children With Chronic Spontaneous Urticaria
    Dupixent Approval For Children With Chronic Spontaneous Urticaria

    22 Apr 2026

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-21-30-00-3279472

    PRESS RELEASE
    22 Apr 2026
    Share Share
    Dupixent Receives EU Approval For Young Children With CSU
    Dupixent Receives EU Approval For Young Children With CSU

    13 Apr 2026

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-13-05-00-00-3272182

    PRESS RELEASE
    13 Apr 2026
    Share Share
    Dupixent Approved in Japan for Bullous Pemphigoid (BP)
    Dupixent Approved in Japan for Bullous Pemphigoid (BP)

    24 Mar 2026

    // PRESS RELEASE

    https://investor.regeneron.com/news-releases/news-release-details/dupixentr-dupilumab-approved-japan-first-targeted-medicine-treat

    PRESS RELEASE
    24 Mar 2026
    Share Share

    Global Sales Information

    Do you need Business Intel? Ask us

    US Medicaid Prescriptions

    read-more
    read-more

    01

    Brand Name : Dupixent Pen

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent Pen

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 1,081,417,351

    Year : 2023

    Prescribers : 41263

    Prescriptions : 274533

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Dupixent Syringe

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent Syringe

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 633,292,043

    Year : 2023

    Prescribers : 20849

    Prescriptions : 160290

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Dupixent Pen

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent Pen

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 522,507,412

    Year : 2022

    Prescribers : 23350

    Prescriptions : 141331

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Dupixent Syringe

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent Syringe

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 555,582,625

    Year : 2022

    Prescribers : 19441

    Prescriptions : 149070

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Dupixent Pen

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent Pen

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 206,771,544

    Year : 2021

    Prescribers : 11232

    Prescriptions : 59564

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Dupixent Syringe

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent Syringe

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 525,931,872

    Year : 2021

    Prescribers : 19395

    Prescriptions : 149990

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Dupixent Pen

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent Pen

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 13,385,380

    Year : 2020

    Prescribers : 1720

    Prescriptions : 3902

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Dupixent Syringe

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent Syringe

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 466,761,590

    Year : 2020

    Prescribers : 19113

    Prescriptions : 137656

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 265,809,525

    Year : 2019

    Prescribers : 13171

    Prescriptions : 81158

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Company : Sanofi-Aventis

    Dupilumab

    Drug Cost (USD) : 101,803,038

    Year : 2018

    Prescribers : 5220

    Prescriptions : 32059

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Annual Reports

    read-more
    read-more

    01

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Dupilumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2019 Revenue in Millions : 2,261

    2018 Revenue in Millions : 859

    Growth (%) : 163

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Dupilumab

    Main Therapeutic Indication : Dermatology

    Currency : USD

    2020 Revenue in Millions : 4,275

    2019 Revenue in Millions : 2,551

    Growth (%) : 68

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Dupilumab

    Main Therapeutic Indication : Dermatology

    Currency : USD

    2021 Revenue in Millions : 5,779

    2020 Revenue in Millions : 3,852

    Growth (%) : 49

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Dupilumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2022 Revenue in Millions : 9,095

    2021 Revenue in Millions : 5,779

    Growth (%) : 57

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Dupilumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2023 Revenue in Millions : 11,565

    2022 Revenue in Millions : 9,095

    Growth (%) : 29

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Dupilumab

    Main Therapeutic Indication : Immunology

    Currency : USD

    2024 Revenue in Millions : 13,557

    2023 Revenue in Millions : 11,565

    Growth (%) : 17

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Dupilumab

    Main Therapeutic Indication : Dermatology

    Currency : USD

    2017 Revenue in Millions : 272

    2016 Revenue in Millions : 0

    Growth (%) : New Launch

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Dupixent

    France
    arrow
    PEGS Boston Summit
    Not Confirmed
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Dupilumab

    Main Therapeutic Indication : Dermatology

    Currency : USD

    2018 Revenue in Millions : 890

    2017 Revenue in Millions : 247

    Growth (%) : 260%

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Dupixent

    Dupilumab

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Regeneron

    Dupilumab

    Main Therapeutic Indication : Dermatology

    Currency : USD

    2020 Revenue in Millions : 3,226

    2019 Revenue in Millions : 1,871

    Growth (%) : 72

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Dupixent

    Dupilumab

    arrow
    PEGS Boston Summit
    Not Confirmed

    Brand Name : Dupixent

    U.S.A
    arrow
    PEGS Boston Summit
    Not Confirmed

    Regeneron

    Dupilumab

    Main Therapeutic Indication : Dermatology

    Currency : USD

    2017 Revenue in Millions : 256

    2016 Revenue in Millions : New Launch

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    Health Canada Patents

    read-more
    read-more

    01

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2029-10-27

    Date Granted : 2017-02-28

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2737044

    Filing Date : 2009-10-27

    Strength per Unit : 150 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2029-10-27

    Date Granted : 2017-02-28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2031-10-05

    Date Granted : 2019-01-15

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2813587

    Filing Date : 2011-10-05

    Strength per Unit : 150 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2031-10-05

    Date Granted : 2019-01-15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2033-09-04

    Date Granted : 2022-01-11

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2883936

    Filing Date : 2013-09-04

    Strength per Unit : 150 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2033-09-04

    Date Granted : 2022-01-11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2034-07-10

    Date Granted : 2021-11-16

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2917804

    Filing Date : 2014-07-10

    Strength per Unit : 150 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2034-07-10

    Date Granted : 2021-11-16

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2029-10-27

    Date Granted : 2017-02-28

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2737044

    Filing Date : 2009-10-27

    Strength per Unit : 200mg / 1.14mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2029-10-27

    Date Granted : 2017-02-28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2031-10-05

    Date Granted : 2019-01-15

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2813587

    Filing Date : 2011-10-05

    Strength per Unit : 200mg / 1.14mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2031-10-05

    Date Granted : 2019-01-15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2033-09-04

    Date Granted : 2022-01-11

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2883936

    Filing Date : 2013-09-04

    Strength per Unit : 200mg / 1.14mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2033-09-04

    Date Granted : 2022-01-11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2029-10-27

    Date Granted : 2017-02-28

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2737044

    Filing Date : 2009-10-27

    Strength per Unit : 150 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2029-10-27

    Date Granted : 2017-02-28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2031-10-05

    Date Granted : 2019-01-15

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2813587

    Filing Date : 2011-10-05

    Strength per Unit : 150 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2031-10-05

    Date Granted : 2019-01-15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Sanofi-Aventis Canada Inc.

    DUPILUMAB
    arrow
    PEGS Boston Summit
    Not Confirmed

    Sanofi-Aventis Canada Inc.

    Country
    arrow
    PEGS Boston Summit
    Not Confirmed

    Patent Expiration Date : 2033-09-04

    Date Granted : 2022-01-11

    DUPILUMAB

    Brand Name : DUPIXENT

    Patent Number : 2883936

    Filing Date : 2013-09-04

    Strength per Unit : 150 mg / mL

    Dosage Form : SOLUTION

    Human Or VET : Human

    Route of Administration : SUBCUTANEOUS

    Patent Expiration Date : 2033-09-04

    Date Granted : 2022-01-11

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search